Phase 3 Neuroprotection Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
Congenital Heart Disease in ChildrenNeuroprotection
dr. M.J.N.L. Benders236 enrolled4 locationsNCT04217421
Active
Phase 3
A randomised controlled trial of antenatal melatonin supplementation in fetal growth restriction for fetal neuroprotection.
Fetal NeuroprotectionFetal Growth Restriction (FGR)
Monash Health336 enrolled14 locationsACTRN12617001515381
Completed
Phase 3
MAGENTA - Magnesium Sulphate at 30 to 34 weeks' gestational age: Neuroprotection Trial
Complications of preterm infantCerebral PalsyNeuroprotection
University of Adelaide1,676 enrolled1 locationACTRN12611000491965